Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Senores Pharmaceuticals Ltd.
Change Company   
BSE Code 544319
ISIN Demat INE0RB801010
Book Value 155.63
NSE Code SENORES
Dividend Yield % 0.00
Market Cap 35585.61
P/E 258.05
EPS 2.99
Face Value 10  
21-Jan-2026 Senores Pharmaceuticals informs about press relea...
20-Jan-2026 Senores Pharmaceuticals informs about financial r...
20-Jan-2026 Senores Pharmaceuticals informs about revised med...
12-Jan-2026 Senores Pharmaceuticals informs about newspaper ...
07-Jan-2026 Allotment of Equity Shares
05-Jan-2026 Allotment of Equity Shares
01-Jan-2026 Senores Pharmaceuticals informs about disclosure
16-Dec-2025 Senores Pharmaceuticals gets nod to acquire 100% ...
16-Dec-2025 Senores Pharmaceuticals gains on getting nod to a...
05-Dec-2025 Senores Pharmaceuticals gets marketing authorizat...
05-Dec-2025 Senores Pharmaceuticals informs about disclosure
07-Nov-2025 Senores Pharmaceuticals informs about newspaper p...
08-Oct-2025 Senores Pharmaceuticals informs about compliances...
13-Aug-2025 Senores Pharmaceuticals signs agreement to acquir...
13-Aug-2025 Senores Pharmaceuticals gains on signing agreemen...
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.